Blueprint Medicines — Corporate Update (March 2020)
43 slides from Blueprint Medicines's corporate update, Mar 16, 2020
Slide 1: PIONEER clinical trial in indolent systemic mastocytosis: Part 1 Data & Program Update
© 2020 Blueprint Medicines Corporation R.S., living with systemic mastocytosis PIONEER clinical trial in indolent systemic mastocytosis PART 1 DATA & PROGRAM UPDATE MARCH 16, 2020
Slide 2: Forward-looking statements
Forward-looking statements 2 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “
Slide 3: Blueprint Medicines call participants
Blueprint Medicines call participants Introduction Kristin Hodous, Sr. Manager, Investor Relations Overview of avapritinib program in SM Jeff Albers, Chief Executive Officer Updated data from Part 1 of the PIONEER trial in indolent SM Brenton Mar, MD, PhD, Senior Medical Director Registration strate
Slide 4: Target profile of a transformative therapy for systemic mastocytosis
Target profile of a transformative therapy for systemic mastocytosis 4 Potent inhibitor of KIT D816V, the SM disease driver Improves patient-reported quality of life Reduces mast cell burden Improves disease symptoms to deliver meaningful clinical benefit Not for promotional use. Favorable safety pr
Slide 5: Robust body of data for avapritinib establishes the foundation in SM
Robust body of data for avapritinib establishes the foundation in SM 1 Presented at American Society of Hematology (ASH) 2016 Annual Meeting. Data cutoff: November 11, 2016. 2 Presented at ASH 2017 Annual Meeting. Data cutoff: October 4, 2017. 3 Presented at ASH 2018 Annual Meeting. Data cutoff: Sep
Slide 6: Avapritinib is the only highly potent inhibitor of KIT D816V
Avapritinib is the only highly potent inhibitor of KIT D816V, the common disease driver across systemic mastocytosis 1 Analysis of trial data from EXPLORER and PATHFINDER (data cutoff: August 30, 2019) and PIONEER (data cutoff: December 27, 2019). 2 Jawhar, et al. Response and progression on midosta
Slide 7: Systemic mastocytosis represents a substantial portfolio value driver
GIST OPPORTUNITY a RET OPPORTUNITY 0 SM OPPORTUNITY ~8,000 patients ~75,000 patients ~10,000 patients Systemic mastocytosis represents a substantial portfolio value driver 7 Figures are illustrative. Approximate number of patients in major markets (US, EU5 and Japan) based on estimated prevalence fo
Slide 8: Multiple significant clinical data disclosures planned in 2020
Multiple significant clinical data disclosures planned in 2020 ISM, indolent systemic mastocytosis; GIST, gastrointestinal stromal tumors. MTC, medullary thyroid cancer; NSCLC, non-small cell lung cancer. 8 Q1 2020 Q2 2020 Q3 2020 • Top-line ARROW data for pralsetinib in RET+ NSCLC • Updated PIONEER
Slide 9: PIONEER: Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Avapritinib
PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy American Academy of Allergy Asthma and Immunology Annual Meeting March 16, 2020 Cem Akin, Ha
Slide 10: Disclosures
10 Disclosures • AYVAKIT™ (avapritinib) is approved by the FDA for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations, in the United States
Slide 11: Systemic mastocytosis is a clonal mast cell neoplasm driven by KIT D816V
Systemic mastocytosis (SM) is a clonal mast cell (MC) neoplasm driven by KIT D816V Hyperactivation and proliferation Debilitating mediator symptoms in skin, gastrointestinal and neurocognitive areas Significant symptom directed polypharmacy SM Prevalence of ~1:10,000 ~32,000 estimated in US ~5% Adva
Slide 12: Avapritinib targets D816V with objective and symptomatic responses in SM
Avapritinib targets D816V with objective and symptomatic responses in SM Phase 1 EXPLORER trial Highly selective kinome profile Highly potent on KIT D816V Objective responses in AdvSM 77% confirmed ORR2 in Advanced SM at ≥200mg once daily Responses deepen over time FDA Breakthrough Designation for A
Slide 13: Phase 2 PIONEER clinical trial in non-advanced SM: Part 1
BSC, best supportive care; PK, pharmacokinetics; PRO, patient-reported outcome; RP2D, recommended part 2 dose. Phase 2 PIONEER clinical trial in patients with non-advanced SM Part 1: Dose Selection (fully enrolled) primary endpoint After determination of RP2D and analysis of Part 1, Part 2 opens Sel
Slide 14: Phase 2 PIONEER clinical trial in non-advanced SM: Part 2
ECOG, Eastern Cooperative Oncology Group TSS, total symptom score; WHO, World Health Organization. 14 Phase 2 PIONEER clinical trial in patients with non-advanced SM Part 2: Pivotal Efficacy (pending) Registration-enabling portion powered to demonstrate efficacy over placebo primary endpoint seconda
Slide 15: Baseline patient and disease characteristics
aLocal quantitative and qualitative KIT testing of bone marrow and/or blood, various methods and sensitivities. bNGS=next generation sequencing targeted myeloid panel (central) in blood, algorithmic calling sensitivity to 1.9% MAF; cdigital droplet PCR in blood (central), sensitivity to 0.02% MAF, d
Slide 16: ISM-SAF patient reported outcomes tool for ISM
ISM-SAF, a reliable construct valid patient reported outcomes tools for ISM • Clinical benefit measure and primary endpoint for PIONEER trial • Designed with input from disease experts, patients and regulatory authorities to support regulatory approval ISM-SAF Symptom Score Groups Abdominal pain Sco
Slide 17: Significant baseline sign and symptom burden in patients enrolled on PIONEER
Significant baseline sign and symptom burden in patients enrolled on PIONEER • Every patient with significant symptom burden at baseline • Most severe symptoms in the 14 days prior to dosing were fatigue, brain fog, flushing and spots • >99% daily adherence to ISM-SAF entry by patients • Mean Total
Slide 18: MC-QOL, a Quality of Life questionnaire for patients with ISM
18 MC-QOL, a Quality of Life questionnaire for patients with ISM • A quality of life tool developed for mastocytosis • 27 questions across 4 domains: Skin, Symptoms, Social Life/Functioning and Emotions • 2 week recall, performed at every study visit • Each domain with 3 to 9 symptoms, each domain s
Slide 19: Well tolerated safety profile across all doses
Well tolerated safety profile across all doses with no grade 3 AEs at 25 mg AE in >15% of placebo or avapritinib arms avapritinib Preferred term Placebo n=9 25 mg n=10 50 mg n=10 100 mg n=10 % of subjects with ≥1 AE any grade grade 3 any grade grade 3 any grade grade 3 any grade grade 3 89 22 100 0
Slide 20: Avapritinib significantly improves overall SM symptoms compared to placebo
Avapritinib significantly improves overall SM symptoms compared to placebo • ~30% mean symptom reduction at 16 weeks in avapritinib treated patients measured by ISM-SAF TSS • ~3% mean symptom reduction in placebo • Difference is statistically significant (p=0.001) at 16 weeks of therapy n is number
Slide 21: Avapritinib 25 mg QD achieves similar reduction to 100 mg QD by week 16
21 Avapritinib 25 mg QD achieves similar reduction to 100 mg QD by week 16 • 25 mg QD demonstrates similar % reduction in mean symptom burden to 100 mg dose at week 16 avapritinib 25 mg QD selected as the RP2D 25 mg dose provided similar mean improvements as higher doses with better tolerability -5
Slide 22: Symptom reduction in GI, Skin and Neurocognitive groups compared to placebo
22 Avapritinib 25 mg QD achieves symptom reduction in GI, Skin and Neurocognitive symptom groups compared to placebo placebo avapritinib 25 mg QD
Slide 23: Avapritinib improves most bothersome symptom group
23 Avapritinib 25 mg QD improves most bothersome symptom group -5 0 -4 0 -3 0 -2 0 -1 0 0 W e e k s M o s t B o t h e r s o m e S y m p t o m G r o u p a t B a s e l i n e m e a n % c h a n g e f r o m b a s e l i n e 0 4 8 12 16 a v a p ritin ib 2 5 m g (n = 1 0 ) p la c e b o (n = 9 ) • Improvemen
Slide 24: Avapritinib 25mg QD improves individual symptoms compared to placebo
24 Avapritinib 25mg QD improves individual symptoms compared to placebo placebo avapritinib 25 mg QD
Slide 25: Improvements in Quality of Life by MC-QoL
Improvements in Quality of Life with avapritinib 25mg QD by MC-QoL MC-QoL total score placebo avapritinib 25 mg QD -5 0 -4 0 -3 0 -2 0 -1 0 0 1 0 W e e k s M C - Q o L T o t a l S c o r e M e a n % c h a n g e f r o m b a s e l i n e p la c e b o (n = 9 ) a v a p ritin ib 2 5 m g (n = 1 0 ) 0 4 8 12
Slide 26: Objective reductions in mast cell burden vs placebo
26 Objective reductions in mast cell burden at 25 mg vs placebo *Bone marrow MC assessment in SM may have variability in sampling due to patchy nature of disease. No patient on study has progressed to advanced disease. #patient received high dose IV steroids. # # #
Slide 27: Summary of PIONEER Part 1 results
• Avapritinib treatment results in a statistically significant reduction in total symptom score at 16 weeks • Avapritinib has a favorable safety profile in patients with indolent SM, supporting further evaluation of a chronic dosing regimen • 95% of patients remain on study, with no discontinuations
Slide 28: Registration strategy in indolent SM
Registration strategy in indolent SM Andy Boral, MD, PhD, Chief Medical Officer
Slide 29: Blueprint Medicines is pioneering the path to registration in indolent SM
Blueprint Medicines is pioneering the path to registration in indolent SM Lowest effective dose to enable chronic treatment Validated, clinically important outcome measures Efficient registration-enabling clinical trial design Not for promotional use. 29
Slide 30: Safety results for avapritinib 25mg QD are similar to placebo at 16 weeks
Safety results for avapritinib 25mg QD are similar to placebo at 16 weeks 30 AE in >15% of placebo or avapritinib arms avapritinib Preferred term Placebo n=9 25 mg n=10 % of subjects with ≥1 AE any grade grade 3 any grade grade 3 89 22 100 0 Nausea 22 0 10 0 Dizziness 22 0 30 0 Headache 11 0 30 0 Di
Slide 31: The ISM-SAF and MC-QoL outcome measures are highly correlated
The ISM-SAF and MC-QoL outcome measures are highly correlated Data cutoff: December 27, 2019. 31 Correlation from baseline to Week 16 • Pearson correlation co-efficient: 0.65 • Spearman correlation co-efficient: 0.69 Mean change in ISM-SAF TSS and MC-QoL (All avapritinib cohorts versus placebo) MC-Q
Slide 32: Avapritinib improves all quality of life domains measured by MC-QoL
Avapritinib 25 mg QD improves all quality of life domains measured by the MC-QoL by 16 weeks Data cutoff: December 27, 2019. 32 Not for promotional use. Avapritinib 25 mg QD Placebo -38.5 -50.0 -45.5 -26.8 -0.1 1.7 12.7 -4.2
Slide 33: Clinically meaningful changes in disease severity by MC-QoL
Avapritinib 25 mg QD demonstrates clinically meaningful changes in disease severity, as measured by the MC-QoL 1 PIONEER trial analysis of patients with MC-QoL responses at baseline and 16 weeks. Data cutoff: December 27, 2019. 2 Siebenhaar, et al. Development and Validation of the Mastocytosis Qual
Slide 34: Patient case: female with ISM on avapritinib 25 mg QD
36 year old female with ISM previously diagnosed with cutaneous mastocytosis Rear right leg At week 24 Baseline Abdomen 0 4 8 1 2 1 6 2 0 2 4 0 2 0 4 0 6 0 8 0 0 2 0 4 0 6 0 8 0 1 0 0 W e e k s S c o r e S e r u m T r y p t a s e ( n g / m L ) IS M -S A F T S S T ry p ta se M C -Q o L T o ta l At Ba
Slide 35: Next steps for PIONEER trial of avapritinib in indolent SM
Next steps for PIONEER trial of avapritinib in indolent SM 35 RP2D 25 mg QD PIONEER Registration-enabling Part 2 Planned initiation June 2020 PIONEER Dose-finding Part 1 Complete Change in ISM-SAF total symptom score PIONEER REGISTRATION-ENABLING PART 2 Design: Randomized, double-blind, placebo-cont
Slide 36: Opportunity to deliver therapeutic value to patients with SM
Opportunity to deliver therapeutic value to patients with SM Christy Rossi, Chief Commercial Officer
Slide 37: Systemic mastocytosis is a rare disease with high medical need
Systemic mastocytosis is a rare disease with high medical need and a population size comparable to cystic fibrosis and hemophilia 1 Based on estimated prevalence for advanced, indolent and smoldering SM. 2 Cystic Fibrosis Foundation website. Available at: www.cff.org/What-is-CF/About-Cystic- Fibrosi
Slide 38: Most patients with ISM experience debilitating symptoms
Most patients with ISM experience debilitating symptoms that profoundly impact their quality of life 1 Review of patient medical histories for PIONEER trial placebo cohort. 2 Data cutoff: December 27, 2019. 38 At baseline, patients in PIONEER had multiple unresolved morbidities related to their ISM:
Slide 39: Management of ISM often requires extensive healthcare system utilization
Management of ISM often requires extensive healthcare system utilization 1 Mast Cell Connect registry data on file. Enrollment initiated December 1, 2015. Data cutoff: August 20, 2019. 2 Jennings S et al. J Allergy Clin Immunol Pract. 2014;2(1):70-76. 39 92% 58% Has the participant ever been admitte
Slide 40: Finding patients is about looking for them
Finding patients is about looking for them 40 German Registry on Disorders of Eosinophils and Mast Cells; Schwaab et al., DGHO 2019; Graphic courtesy of Andreas Reiter. Mannheim Aachen German experience: SM patients are found near centers with capacity to diagnose We are now actively engaging to e
Slide 41: Avapritinib has an unparalleled clinical profile
Avapritinib is the only highly potent inhibitor of KIT D816V, the genetic driver of SM, and has an unparalleled clinical profile Data reported at AAAAI Annual Meeting in March 2020. Data cutoff: December 27, 2019. 41 -5 0 -4 0 -3 0 -2 0 -1 0 0 1 0 W e e k s I S M - S A F T o t a l S y m p t o m S c
Slide 42: Questions & answers
(Sbwuepriat. Questions & answers
Slide 43: Pipeline footnotes
1. Unresectable or metastatic disease. 2. CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines retains all rights in the rest of the world. 3. Approved in the U.S. for the